摘要:
The invention relates to tetracyclo[6.6.2.0 .0 ]hexadeca-2(7),3,5,9(14),10,12-hexaene derivatives of general formula (I), wherein R1 and R2 are hydrogen or a halogen atom and are the same or different, X is hydrogen and Y is a group -NR3R4 or a group -N CH3R3R4 or X and Y together form a group CH2-NR5, and Z represents a -CH2-group or a C=NH-group.
摘要翻译:本发明涉及四环[6.6.2.0 <2,7> 0.0 <9.14>] hexadeca-2(7),-3,5,9-(14),通式-10,12- hexaenderivate(I),其中R1 和R 2相同或不同,是氢或卤原子,X是氢和Y是基团-NR 3 R 4或基团-N意味着<+> CH3R3R4或X和Y一起形成基团-CH 2 NR 5和Z表示-CH 2基团或 C = NH组。
摘要:
Compounds of general formula (I) wherein A is (a) or (b); Z is (CH2)m or a carbonyl group are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain. Also intermediates to the compounds of formula (I) are claimed.
摘要:
The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
摘要:
Compounds of formula (I), wherein A is selected from (a), (b) (c), (d), (e), (f) and B is selected from (g), (h) and (i), wherein W is a carbonyl, sulphonyl or sulphinyl group, and X is a carbonyl, sulphonyl or sulphinyl group or -C(O)-CH2- (in which the carbonyl group is bonded to Y), provided that at least one of W and X contains carbonyl, Y is R9-O- or R9-N(R10)-, Z is selected from (i), (ii), (iii), (iv) or Z is absent and W is H, with a number of provisions and pharmaceutically acceptable salts thereof are ligands at CCK and/or gastrin receptors.
摘要:
The present invention relates to a process for the preparation of aqueous hydrogen peroxide from the anthraquinone (AO) loop process, comprising using at least one alkylanthraquinone of formula (I) wherein -R1, R2 and R3 are chosen from H, methyl radical, isopropyl radical, n-propyl radical, and tert-amyl radical, and -at least two of the three groups R1, R2 and R3 are different from H and are different from each other.
摘要:
Die vorliegende Erfindung betrifft ein dreistufiges Verfahren zur Synthese 1,1-disubstituierter Olefine, umfassend - in einem ersten Schritt die Reaktion eines 1,3-Diens mit einem Olefin der allgemeinen Formel (I), Formel (I), worin X ein elektronenziehender Substituent und Y ein Wasserstoffatom oder ein Halogenatom ist, wobei X und Y nicht identisch sind, zu einer ungesättigten, die Substituenten X und Y enthaltenden cyclischen Verbindung; - in einem zweiten Schritt die Substitution von Y durch einen Substituenten W, ausgewählt aus einem C 1 -C 12 Kohlenwasserstoffrest, einer C 2 -C 12 Carbonsäureestergruppe, einer C 3 -C 12 Alkoxycarbonylalkylgruppe, einer C 2 -C 12 Alkanoyl-, C 4 -C 12 Cycloalkancarbonyl- oder C 6 -C 12 (Hetero)Arencarbonylgruppe, einer C 1 -C 12 Hydroxyalkylgruppe, einer C 2 -C 12 Phosphonsäureestergruppe, einer C 1 -C 12 Sulfonylgruppe, einer C 1 -C 12 Sulfinylgruppe, einer C 1 -C12 Sulfonsäureestergruppe, einer Aldehydgruppe, einer Carbamoylgruppe, einem Halogenatom und einer Cyangruppe. - in einem dritten Schritt die Abspaltung eines 1,1-disubstituierten Olefins der allgemeinen Formel (II), Formel (II), worin X und W die vorstehende Bedeutung haben.
摘要:
Compounds of formula (I) wherein R and R are independently H, methyl, halo, carboxy, esterified carboxy, amidated carboxy, carboxymethyl, esterified carboxymethyl or amidated carboxymethyl; R and R (or each R and R group, when m or n is 2 or more) are independently selected from halo, amino, nitro, cyano, sulphamoyl, sulphonyl, trifluoromethyl, C1 to C3 alkyl, C1 to C3 alkoxy, hydroxy, C1 to C3 hydroxyalkyl, C1 to C3 alkylcarboxyamino, carboxy, esterified carboxy and amidated carboxy; R and R are independently selected from H and the groups recited above for R ; m is from 0 to 4, provided that m is not more than 2 unless R is exclusively halo; n is from 0 to 4, provided that n is not more than 2 unless R is exclusively halo; R , R and R are independently H or C1 to C3 alkyl; R is H or C1 to C15 hydrocarbyl, in which one or more hydrogen atoms of the hydrocarbyl group may be replaced by a halogen atom, and up to two of the carbon atoms may be replaced by a nitrogen, oxygen or sulphur atom, provided that R does not contain a -O-O-group; U is aryl, substituted aryl, heterocyclic, substituted heterocyclic or cycloalkyl, and Z is a group of formula (II) or (III) (wherein R is H or C1 to C3 alkyl; X is -CO2H or tetrazolyl; Y is H, -CO2H, tetrazolyl, -CH2OH, -CO2Me or -CONH2, and a is from 0 to 2); and pharmaceutically acceptable salts thereof have a high affinity for CCK and/or gastrin receptors.